Dr. Mehmud Joins Medicus As Chief Medical Officer

Medicus Pharma Ltd has announced the appointment of Dr. Faisal Mehmud as Chief Medical Officer. Dr Mehmud brings over two decades of global expertise in clinical development, medical affairs, and drug safety across diverse therapeutic areas, including oncology, haematology, rare diseases, and primary care. He has played a critical role in successfully launching various therapies and led global medical strategies for treatments, from small molecules and antibodies to cell therapies and cytotoxic chemotherapies. Dr. Mehmud has extensive experience in the late phases of clinical development, product launches, and the integration of novel therapies into care pathways, focusing on improved patient outcomes.

“Dr Brennan, as a co-founder of the company, has been instrumental in identifying our lead asset D-MNA and designing the clinical development program to position us to become the first-in-class but also the best-in-class novel therapeutic alternative to treat BCC. Ed is an accomplished bio-pharmaceutical executive, and his elevation to the role of Chief Scientific Officer is very timely as we strengthen our executive team and gallop forward our D-MNA phase 2 study,” stated Dr. Raza Bokhari, Exec. Chairman & CEO.

Dr. Mehmud has held senior positions at leading pharmaceutical companies, including Sanofi, Novartis, Bristol Myers Squibb (BMS), Pfizer, and GlaxoSmithKline (GSK), working across London, Paris, and Philadelphia. Most recently, he served as Senior Vice President of Data Generation and Scientific Communications in Worldwide Global Medical Affairs at GSK, where he led clinical trial programs and medical affairs initiatives. 

Before GSK, he held leadership roles at Pfizer, including Vice President and Worldwide Medical Franchise Head for Precision Medicine and Early Oncology Development, where he advanced oncology projects from early clinical stages to market readiness. At Bristol Myers Squibb, Dr. Mehmud was Vice President of Global Drug Safety, overseeing safety management for complex therapies, including antibody-based and cellular treatments.

Dr. Mehmud holds a medical degree from the University of Cambridge and a diploma in internal medicine and pharmaceutical medicine from the Royal College of Physicians. The UK General Medical Council licenses him. In addition, Medicus Pharma has promoted Dr Edward J. Brennan to Chief Scientific Officer and Head of R&D. 

Previously, the company’s Chief Medical Officer, Dr Brennan, is an experienced pharmaceutical leader with over 30 years of expertise across all phases of clinical development. His Wyeth, GlaxoSmithKline, and IndiPharm work contributed to 10 FDA drug approvals. Dr. Brennan’s areas of specialization include immunology, oncology, women’s health, and genetic diseases. 

Before transitioning to the pharmaceutical industry, he practiced as a general surgeon. Dr. Brennan earned a Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science. He later pursued medicine at the Royal College of Surgeons in Ireland, ultimately earning his medical degree from Temple University School of Medicine.

“We are thrilled to welcome Dr. Mehmud to our leadership team. Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high-impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvable doxorubicin-containing microneedle array (D-MNA) to treat non-melanoma skin cancer, especially basal cell carcinoma,” said Dr. Raza Bokhari, Exec. Chairman & CEO.